Skip to main content
IAS 2023

A preview of the science at IAS 2023


IAS 2023, the 12th IAS Conference on HIV Science, will bring together experts from across the worlds of science, policy and activism to examine the latest advances in HIV research and forge a more equitable and innovative HIV response. Below is a sample of the scientific highlights you can expect at IAS 2023. For more details, check out the full online programme.

alternative text

Track A: Basic science

  • A new case of HIV remission for 18 months without ART following a bone marrow transplant with wild-type CCR5 donor cells

  • Insights on differences in sustained aviremia without ART between female and male children following in utero HIV transmission

  • A novel cure study examining potent, HIV-specific latency reversal through CRISPR activation delivered by lipid nanoparticles

  • Novel findings demonstrating that the frontal lobe is a major reservoir of intact HIV proviral DNA in the brain despite viral suppression with ART

  • New evidence that post-treatment controllers exhibit distinct CD8+ T cell features before and after ART interruption

  • A study showing that venetoclax, which is currently used as a cancer medication, depletes cells with latent HIV and delays rebound in humanized mice

Track B: Clinical science 

  • Full results from the REPRIEVE trial, which was stopped early when an interim analysis showed that participants living with HIV who took a daily statin lowered their risk of major adverse cardiovascular events by 35% 

  • An important update on PEPFAR tuberculosis preventive treatment coverage and remaining gaps among people living with HIV

  • Results of an open-label study evaluating the pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed pregnant women with HIV

  • Insights on a biodegradable, subcutaneous implant delivery platform that could treat HIV for up to six months in young children

  • Findings from an effort to transform three short-acting HIV drugs – tenofovir, lamivudine, and dolutegravir (TLD) – into a novel, long-acting triple therapy in a single injectable dosage

Track C: Epidemiology and prevention science 

  • New WHO data showing high in-hospital mortality among people living with HIV and COVID-19 during the pre-Delta, Delta, and Omicron variant waves

  • Results from a randomized controlled trial examining the efficacy of voluntary medical male circumcision in preventing HIV among men who have sex with men

  • An important study examining whether PrEP use during pregnancy is associated with lower bone mineral density in young children

  • The latest data on COVID-19 vaccine effectiveness by HIV status and injection drug use history

  • A 16-country study examining the extent to which women living with HIV experience coercion by healthcare providers related to sterilization, family planning, pregnancy, and feeding practices

  • A global systematic review and meta-analysis quantifying HIV treatment outcomes among people who inject drugs

Track D: Social and behavioral sciences

  • Results from the HPTN 084 open-label extension examining whether cisgender women in sub-Saharan Africa prefer long-acting injectable or daily oral PrEP for HIV prevention

  • New evidence from Zimbabwe that the dapivirine vaginal ring is an acceptable and feasible alternative to daily oral PrEP for HIV prevention

Track E: Implementation science, economics, systems and synergies

  • Insights on the use of artificial intelligence to interpret images of HIV self-testing results

  • Results from a study examining the cost effectiveness of long-acting injectable cabotegravir (CAB-LA) as PrEP among adolescent girls and young women in South Africa

The IAS promotes the use of non-stigmatizing, people-first language. The translations are all automated in the interest of making our content as widely accessible as possible. Regretfully, they may not always adhere to the people-first language of the original version.